Search This Blog

Sunday, October 25, 2026

Xencor's XmAb819 Phase 1 data in advanced clear cell renal cell carcinom enable global randomized trial

 Xencor's XmAb819 Phase 1 data in advanced clear cell renal cell carcinoma support 400 mcg/kg IV dose, enable global randomized trial, accelerated approval path

https://finviz.com/stock?t=XNCR&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)